These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33496313)

  • 41. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
    Circulation; 2017 Apr; 135(16):1481-1489. PubMed ID: 28179398
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Colchicine on Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and One-Stage and Two-Stage Meta-Analysis of Randomized-Controlled Trials.
    Teo YN; Teo YH; Syn NL; Goh MW; Yoong CSY; Lee CH; Chan MY; Chai P; Yeo TC; Sia CH
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):343-354. PubMed ID: 34003455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting Inflammation to Reduce Residual Cardiovascular Risk.
    Ajala ON; Everett BM
    Curr Atheroscler Rep; 2020 Sep; 22(11):66. PubMed ID: 32880743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death.
    Sáez ME; González-Pérez A; Johansson S; Himmelmann A; García Rodríguez LA
    Eur J Prev Cardiol; 2016 Jul; 23(10):1029-36. PubMed ID: 26603743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): The Past, Present, and Future Management.
    Pasupathy S; Tavella R; Beltrame JF
    Circulation; 2017 Apr; 135(16):1490-1493. PubMed ID: 28416521
    [No Abstract]   [Full Text] [Related]  

  • 46. Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial.
    Kraler S; Wenzl FA; Lüscher TF
    Eur J Clin Invest; 2020 Dec; 50(12):e13424. PubMed ID: 33091147
    [No Abstract]   [Full Text] [Related]  

  • 47. [Prevention of coronary atherosclerosis. Determination and evaluation of lipid metabolism values].
    Cremer P; Nagel D; Seidel D
    Fortschr Med; 1995 Nov; 113(32):453-8. PubMed ID: 8543271
    [No Abstract]   [Full Text] [Related]  

  • 48. [Prevention of myocardial infarcts. Facts and myths].
    Stiefelhagen P
    MMW Fortschr Med; 2006 May; 148(18):4-6, 8. PubMed ID: 16736675
    [No Abstract]   [Full Text] [Related]  

  • 49. Letter by Ciliberti and Capucci Regarding Article, "Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease".
    Ciliberti G; Capucci A
    Circulation; 2017 Sep; 136(11):1080-1081. PubMed ID: 28893966
    [No Abstract]   [Full Text] [Related]  

  • 50. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome.
    Martínez GJ; Robertson S; Barraclough J; Xia Q; Mallat Z; Bursill C; Celermajer DS; Patel S
    J Am Heart Assoc; 2015 Aug; 4(8):e002128. PubMed ID: 26304941
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secondary and tertiary prevention with calcium antagonists in coronary artery disease.
    Burkart F
    Drugs; 1992; 43 Suppl 1():37-42. PubMed ID: 1378787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Response by Lindahl et al to Letter Regarding Article, "Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease".
    Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
    Circulation; 2017 Sep; 136(11):1082-1083. PubMed ID: 28893967
    [No Abstract]   [Full Text] [Related]  

  • 53. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.
    Akodad M; Lattuca B; Nagot N; Georgescu V; Buisson M; Cristol JP; Leclercq F; Macia JC; Gervasoni R; Cung TT; Cade S; Cransac F; Labour J; Dupuy AM; Roubille F
    Arch Cardiovasc Dis; 2017; 110(6-7):395-402. PubMed ID: 28065445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Will Colchicine Soon Be Part of Primary and Secondary Cardiovascular Prevention?
    Samuel M; Waters DD
    Can J Cardiol; 2020 Nov; 36(11):1697-1699. PubMed ID: 32585327
    [No Abstract]   [Full Text] [Related]  

  • 55. Prevention of myocardial infarction.
    Dawber TR; Thomas HE
    Prog Cardiovasc Dis; 1971 Jan; 13(4):343-60. PubMed ID: 5212390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Role of Colchicine in Coronary Artery Disease.
    Butt AK; Cave B; Maturana M; Towers WF; Khouzam RN
    Curr Probl Cardiol; 2021 Mar; 46(3):100690. PubMed ID: 32994053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revascularization versus medical treatments in stable coronary artery disease: predicting the future of novel drug therapies for stable angina.
    Risos L; Berkenboom G
    J Cardiovasc Pharmacol; 2014 Mar; 63(3):213-7. PubMed ID: 24336013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Recommendations for primary and secondary prevention of coronary heart disease].
    Gohlke H; Kübler W
    Z Kardiol; 2002; 91 Suppl 2():1-2. PubMed ID: 12436759
    [No Abstract]   [Full Text] [Related]  

  • 59. The Role of Colchicine in the Prevention of Cerebrovascular Ischemia.
    Tsivgoulis G; Katsanos AH; Giannopoulos G; Panagopoulou V; Jatuzis D; Lemmens R; Deftereos S; Kelly PJ
    Curr Pharm Des; 2018; 24(6):668-674. PubMed ID: 29336246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Change of lifestyle as a relevant therapy after myocardial infarction].
    Janion M; Bakowski D
    Przegl Lek; 2000; 57(9):469-73. PubMed ID: 11199867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.